1. Scrip
  2. >>Business
  3. >>Strategy

Alnylam Offering Value-Based Deals In EU For Breakthrough RNAi Drug Onpattro

 
• By Sten Stovall

Alnylam's president tells Scrip the RNAi pioneer is offering outcomes-based contracts for its first ever product to payers in the European Union following Onpattro's approval there in August. He also says payers "must pay for innovation."

Value-Cost
Alnylam offering value- or outcomes-based Onpattro contracts linked to improvements. • Source: Shutterstock

Mirroring its approach in the US, Alnylam Pharmaceuticals Inc. is offering outcomes-based contracts for its small interfering RNA (siRNA) therapeutic Onpattro (patisiran) in the rare disease of hereditary transthyretin-mediated amyloidosis, and has already launched the gene-silencing drug in Germany, the group's president Barry Greene told Scrip.

"We like to be as innovative on the commercial side as we have been on the R&D side. When we...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

More from Business

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.